These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15257874)

  • 21. [The mistletoe myth--claims, reality and provable perspectives].
    Gabius HJ; André S; Kaltner H; Siebert HC; von der Lieth CW; Gabius S
    Z Arztl Fortbild (Jena); 1996 Apr; 90(2):103-10. PubMed ID: 8686332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Value of mistletoe lectin standardized mistletoe extract for evaluating antitumor properties].
    Mengs U; Witthohn K; Schwarz T; Lentzen H
    Wien Med Wochenschr; 1999; 149(8-10):262-4. PubMed ID: 10483695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparative studies on the immunoactive action of galactoside-specific mistletoe lectin. Pure substance compared to the standardized extract].
    Beuth J; Ko HL; Tunggal L; Geisel J; Pulverer G
    Arzneimittelforschung; 1993 Feb; 43(2):166-9. PubMed ID: 7681287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mistletoe in the treatment of cancer].
    Bruseth S; Enge A
    Tidsskr Nor Laegeforen; 1993 Mar; 113(9):1058-60. PubMed ID: 8493669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro.
    Seifert G; Jesse P; Laengler A; Reindl T; Lüth M; Lobitz S; Henze G; Prokop A; Lode HN
    Cancer Lett; 2008 Jun; 264(2):218-28. PubMed ID: 18314258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients.
    Lenartz D; Stoffel B; Menzel J; Beuth J
    Anticancer Res; 1996; 16(6B):3799-802. PubMed ID: 9042260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recognition of different antigens of mistletoe extracts by anti-mistletoe lectin antibodies.
    Stein GM; Pfüller U; Berg PA
    Cancer Lett; 1999 Jan; 135(2):165-70. PubMed ID: 10096425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomodulating ability of galactoside-specific lectin standardized and depleted mistletoe extract.
    Beuth J; Stoffel B; Ko HL; Jeljaszewicz J; Pulverer G
    Arzneimittelforschung; 1995 Nov; 45(11):1240-2. PubMed ID: 8929248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative determination of lectins in mistletoe preparations.
    Jäggy C; Musielski H; Urech K; Schaller G
    Arzneimittelforschung; 1995 Aug; 45(8):905-9. PubMed ID: 7575759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro.
    Stein G; Berg PA
    Eur J Clin Pharmacol; 1994; 47(1):33-8. PubMed ID: 7988621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Lectin compared to mistletoe use: experimental therapy form with preclinically verified risk potential].
    Kuehn JJ; Kovacs E
    Dtsch Med Wochenschr; 2002 Dec; 127(49):2637; author reply 2638. PubMed ID: 12469281
    [No Abstract]   [Full Text] [Related]  

  • 32. Paediatric medulloblastoma cells are susceptible to Viscum album (Mistletoe) preparations.
    Zuzak TJ; Rist L; Eggenschwiler J; Grotzer MA; Viviani A
    Anticancer Res; 2006; 26(5A):3485-92. PubMed ID: 17094471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro response of stimulated B-CLL lymphocytes of patients treated with Viscum album L. extracts.
    Büssing A; Kochskämper H; Rieger S; Schierholz JM; Schlodder D; Schietzel M
    Anticancer Res; 2007; 27(6B):4195-200. PubMed ID: 18225591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lectin-related use of mistletoe: an experimental form of treatment with preclinically demonstrated potential risks].
    Gabius S; Gabius HJ
    Dtsch Med Wochenschr; 2002 Mar; 127(9):457-9. PubMed ID: 11870561
    [No Abstract]   [Full Text] [Related]  

  • 35. Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract.
    Eisenbraun J; Scheer R; Kröz M; Schad F; Huber R
    Phytomedicine; 2011 Jan; 18(2-3):151-7. PubMed ID: 20724129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer disease predictive diagnosis: BAT/CD3-positive lymphocytes in cancer patients.
    Hardy B; Raiter A; Rubin M; Sprecher E; Sella A; Flex D; Lelcuk S; Bsharah B; Mishaeli M; Niv Y
    Int J Oncol; 2005 Apr; 26(4):971-5. PubMed ID: 15753991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Favourable course of persisting malignant ascites].
    Stange R; Jänsch A; Schrag S; Pflugbeil C; Schlodder D; Pandey-Hoffmann U; Uehleke B
    Forsch Komplementmed; 2009 Feb; 16(1):49-53. PubMed ID: 19295230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease.
    Suzuki H; Graziano DF; McKolanis J; Finn OJ
    Clin Cancer Res; 2005 Feb; 11(4):1521-6. PubMed ID: 15746055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serological markers of pulmonary tuberculosis and of response to anti-tuberculosis treatment in a patient population in Guinea.
    Azzurri A; Kanaujia GV; Sow OY; Bah B; Diallo A; Del Prete G; Gennaro ML
    Int J Immunopathol Pharmacol; 2006; 19(1):199-208. PubMed ID: 16569358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stimulation of the specific immune system by mistletoe extracts.
    Fischer S; Scheffler A; Kabelitz D
    Anticancer Drugs; 1997 Apr; 8 Suppl 1():S33-7. PubMed ID: 9179365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.